- AKTI-1/2
-
- $2.00 / 1kg
-
2019-07-06
- CAS:612847-09-3
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 100kg
|
| | AKTI-1/2 Basic information |
| Product Name: | AKTI-1/2 | | Synonyms: | 1,3-Dihydro-1-[1-[[4-(6-phenyl-1H-imidazo[4,5-g]guinoxalin-7-yl)phenyl]methyl]4-piperidinyl]-2H-benzimidazol-2-on;1,3-Dihydro-1-[1-[[4-(6-phenyl-1H-imidazo[4,5-γ],guinoxalin-7-yl)phenyl]methyl]4-piperidinyl]-2H-benzimidazol-2-one;1,3-Dihydro-1-[1-[[4-(6-phenyl-1H-imidazo[4,5-g]guinoxalin-7-yl)phenyl]methyl]4-piperidinyl]-2H-benzimidazol-2-one;1,3-Dihydro-1-[1-[[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]-4-piperidinyl]-2H-benzimidazol-2-one;2H-BenziMidazol-2-one, 1,3-dihydro-1-[1-[[4-(6-phenyl-1H-iMidazo[4,5-g]quinoxalin-7-yl)phenyl]Methyl]-4-piperidinyl]-;AKT inhibitor VIII (AKTI-1/2);1-(1-(4-(6-Phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)benzyl)-piperidin-4-yl)-1H-benzo[d]imidazol-2(;1-(1-(4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)benzyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one | | CAS: | 612847-09-3 | | MF: | C34H29N7O | | MW: | 551.64 | | EINECS: | 1592732-453-0 | | Product Categories: | Inhibitors;All Inhibitors | | Mol File: | 612847-09-3.mol |  |
| | AKTI-1/2 Chemical Properties |
| Melting point | 242-245°C (dec.) | | density | 1.350±0.06 g/cm3(Predicted) | | storage temp. | Refrigerator | | solubility | insoluble in H2O; insoluble in EtOH; ≥9.2 mg/mL in DMSO | | pka | 7.49±0.50(Predicted) | | form | Yellow solid | | color | White to Yellow to Orange | | CAS DataBase Reference | 612847-09-3 |
| | AKTI-1/2 Usage And Synthesis |
| Chemical Properties | Pale Yellow Solid | | Uses | AKTI-1/2 is a Allosteric Akt (PKB) inhibitors used in synergistic combination therapy for the treatment of cancer. | | Definition | ChEBI: 3-[1-[[4-(7-phenyl-3H-imidazo[4,5-g]quinoxalin-6-yl)phenyl]methyl]-4-piperidinyl]-1H-benzimidazol-2-one is a member of piperidines. | | Biological Activity | akt inhibitor viii is a cell-permeable, reversible and potent, selective inhibitor of akt1, akt2 and akt3 with ic50 values of 58 nm, 210 nm and 2.12 μm, respectively.akt inhibitor viii has shown to remarkably increase anti-proliferation induced by furanodiene in human breast cancer cell mcf-7. akt inhibitor viii could enhance the furanodiene- stimulated akt and p-akt expression decreases as well as increase furanodiene-induced parp cleavage in mcf-7 cells [1].akt inhibitor viii has been revealed to inhibit igf-1-induced akt phosphorylation in a concentration-dependent manner. akt inhibitor viii has also been demonstrated to reduce pras40 phosphorylation in pc12 cells [2]. | | Enzyme inhibitor | This dual Akt1/Akt2 inhibitor (FW = 551.64 g/mol; CAS 612847-09-3; Soluble to 20 mM in DMSO with gentle warming), also named 1,3- dihydro-1-[1-[[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]- methyl]-4-piperidinyl]-2H-benzimidazol-2-one, targets Protein kinase B (PKB) isoforms Akt1 (IC50 = 50 nM) and Akt2 (IC50 = 210 nM), serine/threonine-specific protein kinases that play a key role in multiple cellular processes such as glucose metabolism, apoptosis, cell proliferation, transcription and cell migration. Akti-1/2 is selective for Akt1 and 2 over a panel of other tyrosine and serine/threonine kinases. It also sensitizes LnCaP cells to TRAIL (TNF-related apoptosis-inducing ligand) induced apoptosis. Complete inhibition is achieved in liver cells treated with 1-10 μM. Akti-1/2 also blocks insulin regulation of PEP carboxykinase and glucose 6-phosphatase expression. | | storage | Store at -20°C | | references | [1] zhong z1, dang y, yuan x, guo w, li y, tan w, cui j, lu j, zhang q, chen x, wang y. furanodiene, a natural product, inhibits breast cancer growth both in vitro and in vivo. cell physiol biochem. 2012;30(3):778-90.
[2] wang h1, zhang q, zhang l, little pj, xie x, meng q, ren y, zhou l, gao g, quirion r, zheng w. insulin-like growth factor-1 induces the phosphorylation of pras40 via the pi3k/akt signaling pathway in pc12 cells. neurosci lett. 2012 may 10;516(1):105-9. |
| | AKTI-1/2 Preparation Products And Raw materials |
|